Home › Calculator › MOLN Dividend Calculator 2026
MOLN Dividend DRIP Calculator 2026
45.98% YieldHealthcareMolecular Partners AG · NASDAQ
Price: $4.35 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When MOLN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your MOLN snowball 📈
$10,000 in MOLN → $788109099.06M in 10 years · $65,536,557,071,894.66/month
About Molecular Partners AG (MOLN) — Dividend Analysis 2026
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Compare MOLN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full MOLN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MOLN position with:
🌍 MOLN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MOLN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 45.98% | 43.18% | $4,598 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 39.08% | 36.28% | $3,908 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 36.78% | 33.98% | $3,678 / yr |
| 🇬🇧 UK ISA | 0% | 45.98% | 43.18% | $4,598 / yr |
| 🇬🇧 UK Taxable | 8.75% | 41.96% | 39.16% | $4,196 / yr |
| 🇨🇦 TFSA | 0% | 45.98% | 43.18% | $4,598 / yr |
| 🇨🇦 CA Taxable | 25% | 34.48% | 31.68% | $3,449 / yr |
| 🇦🇺 Super (pension) | 15% | 39.08% | 36.28% | $3,908 / yr |
| 🇦🇺 AU Taxable | 30% | 32.19% | 29.39% | $3,219 / yr |
| 🇩🇪 DE Taxable | 26.375% | 33.85% | 31.05% | $3,385 / yr |
| 🇫🇷 FR Taxable | 30% | 32.19% | 29.39% | $3,219 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MOLN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MOLN Dividend Payment Schedule
MOLN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 MOLN vs Healthcare Benchmarks
How MOLN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MOLN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MOLN Insider Activity
No recent SEC filings reported in the last 90 days.Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where MOLN earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MOLN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Molecular Partners AG (MOLN) is currently trading at $4.35, 85% below its 52-week high. The current dividend yield is 45.98% based on an annual payout of $2.00 per share.
MOLN (Molecular Partners AG) — 45.98% Dividend Yield Analysis
Molecular Partners AG (MOLN) is a healthcare stock currently trading at $4.35 with a dividend yield of 45.98%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (45.98%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.